Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma. - Wang S; Nijland M; Strobbe L; Oosterveld M; Boersma R; Koene H; Klerk C; de Jongh E; Koster A; Pruijt H; van der Poel M; van Werkhoven E; et al. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026)